Objective To investigate the effect of hydroxychloroquine (HCQ) in pregnant women with systemic lupus erythematosus (SLE). Methods In SLE pregnancies of a single Dutch center (2000-2015), lupus activity and flares before and during pregnancy and postpartum were assessed using the SLE Disease Activity Index (SLEDAI)/SLEPDAI (SLEDAI adjusted for pregnancy). The association between HCQ use and p...

In this work the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine (HCQ) was studied. The minimal bactericidal concentration (MBC) of HCQ against the mobile spirochetes was > 32 microg/ml at 37 degrees C, and > 128 microg/ml at 30 degrees C. Incubation with HCQ significantly reduced the conversion of mobile spirochetes to cystic forms. When incubated at 37 ...

INTRODUCTION Hydroxychloroquine (HCQ), 4-aminoquinoline, is an antimalarial drug and has become a basic therapy for rheumatic disease treatment. It can stabilize the condition of SLE patients and reduce the chances of patient relapse through its immunosuppressive function and antiinflammatory effects. This drug was absorbed completely and rapidly by oral administration, but has a prolonged half...

Dear Editor, In the recent article from Ozen et al, the authors found increased risk of diabetes mellitus (DM) in patients with rheumatoid arthritis (RA) compared with normal US adult population. The authors have also reported increased risk of DM in patients with RA who took glucocorticoids (GCs) and statin therapy. Surprisingly, the HR of diabetes has been found to be higher in the statin gro...

Objectives To examine the independent effect of hydroxychloroquine (HCQ) treatment on cardiovascular morbidity among RA patients. Materials and Methods A retrospective cohort study of RA patients treated at Meir medical center between 2003-2013 was conducted. Patients were divided into two groups, those who had been treated with HCQ during the course of their disease and those who had never r...

Chloroquine (CQ) and hydroxychloroquine (HCQ), oral lysosomotropic agents with well-studied toxicity profiles, and antimalarial and antirheumatic activity, have been repurposed as antineoplastic agents based on preclinical data showing efficacy in preinvasive cancer, cancer stem cells and metastatic cancer. Phase I/II clinical trials are providing safety and efficacy data regarding CQ or HCQ mo...

Rheumatoid arthritis is chronic multisystem disease, failure rate with monotherapy is high. The present study was designed to compare the efficacy and safety of triple combination of Methotrexate + Hydroxychloroquine + Sulfasalazine and double combination of Methotrexate + Hydroxychloroquine in patients suffering from Rheumatoid Arthritis. The present study was a prospective, randomized, single...

This study aimed to evaluate the frequency and clinical characteristics of hydroxychloroquine (HCQ) retinopathy in Korean patients with rheumatologic diseases. We retrospectively reviewed medical records of 310 patients taking HCQ. Ophthalmic examinations included spectral-domain optical coherence tomography (SD-OCT), automated visual field test, and fundus autofluorescence. The severity of ret...

Treatment with the antimalarial drug hydroxychloroquine (HCQ) has been associated with reduced risk of thrombosis in the antiphospholipid (aPL) syndrome (APS) and, in an animal model of APS, with reduction of experimentally induced thrombosis. Recognition of 2-glycoprotein I ( 2GPI) by aPL antibodies appears to play a major role in the disease process. We therefore used the techniques of ellips...